Our paper introduces membrane-impermeable caspase inhibitors that use GSDMD pores as their entry route. Because these compounds can't cross an intact membrane, they enter only cells already forming GSDMD pores — before pore density exceeds the cell's repair capacity. This confers built-in specificity: the drug acts solely on pyroptotic cells, leaving apoptosis and healthy cells untouched, addressing the off-target toxicity that has limited earlier, cell-permeable caspase inhibitors. The effect goes beyond arresting cell death. Cells already committed to pyroptosis reverse course and regain viability — a "Lazarus effect" that challenges the assumption that lytic cell death, once initiated, is irreversible. In essence, these unexpected results could create new opportunities for precisely targeting inflammatory cell death while safeguarding healthy tissue.